In agreement with previous studies on AD patients and AD mouse models, the current study shows that GSK-3β expression was decreased in the brains of Aβ1-42-treated mice, and VA treatment increased the expression of Akt and GSK-3β. The gene discussed is GSK3B; the disease is Alzheimer disease.